Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Athebio AG is currently prosecuting 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This indicates a multi-faceted approach to its intellectual property development in the life sciences sector. These 2 actions are assigned to 2 distinct examiners, which provides the company with a broader range of examiner interactions and reduces the risk associated with a single examiner's review style.
The portfolio's activity is concentrated within 1 distinct art unit, suggesting that the technical focus of the applications is closely related despite being reviewed by different individuals. COFFA, SERGIO is identified as the busiest examiner, although he is responsible for only 1 pending office action. Given that there are 2 pending actions in total, the workload is evenly distributed across the 2 distinct examiners. This structure allows the company to navigate the complexities of pharmaceutical patenting through multiple channels within a single technical division of the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
| TSUI, YUNG-SHENG M | 1 | 66.4% | +6.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 1658 | §102§103§112 | Non-Final OA | 86d overdue | Pending | Apr 11, 2024 |
| 18442492 | Variants of Ankyrin Repeat Domains | TSUI, YUNG-SHENG M | — | §112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial